Relmada Therapeutics
Price & Volume
Stats
See moreOpen | $4.40 |
Previous Close | $4.51 |
Day Range | $4.28-$4.43 |
52W Range | $0.24-$5.12 |
Market Cap | $330.7M |
Shares Short | 980,736 |
Financials
See moreRevenue (12 Mos) | $0 |
Revenue Growth (YoY) | 0% |
Gross Profit (12 Mos) | $0 |
Diluted EPS | -$1.78 |
News
See moreYahoo Finance • 26 days ago
Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology
Yahoo Finance • 2 months ago
Relmada signals 2026 launch of two pivotal studies for NDV-01 and sepranolone, supported by $100M financing
Yahoo Finance • 2 months ago
Relmada Therapeutics Reports Third Quarter 2025 Financial Results and Provides Key Clinical, Regulatory, and Corporate Updates
Yahoo Finance • 2 months ago
Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025
About
CEO | Dr. Sergio Traversa M.B.A., Pharm.D. |
Address | 2222 Ponce de Leon Blvd., Coral Gables, FL, United States, 33134 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 17 |
